- Home
- TYRA vs YSG Comparison
TYRA vs YSG Comparison
Compare TYRA & YSG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- YSG
- Stock Information
- Founded
- TYRA 2018
- YSG 2016
- Country
- TYRA United States
- YSG China
- Employees
- TYRA N/A
- YSG N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- YSG Package Goods/Cosmetics
- Sector
- TYRA Health Care
- YSG Consumer Discretionary
- Exchange
- TYRA Nasdaq
- YSG Nasdaq
- Market Cap
- TYRA 422.6M
- YSG 362.5M
- IPO Year
- TYRA 2021
- YSG 2020
- Fundamental
- Price
- TYRA $8.92
- YSG $3.98
- Analyst Decision
- TYRA Strong Buy
- YSG
- Analyst Count
- TYRA 6
- YSG 0
- Target Price
- TYRA $30.50
- YSG N/A
- AVG Volume (30 Days)
- TYRA 353.6K
- YSG 162.0K
- Earning Date
- TYRA 05-08-2025
- YSG 05-21-2025
- Dividend Yield
- TYRA N/A
- YSG N/A
- EPS Growth
- TYRA N/A
- YSG N/A
- EPS
- TYRA N/A
- YSG N/A
- Revenue
- TYRA N/A
- YSG $464,908,550.00
- Revenue This Year
- TYRA N/A
- YSG $16.55
- Revenue Next Year
- TYRA N/A
- YSG $13.17
- P/E Ratio
- TYRA N/A
- YSG N/A
- Revenue Growth
- TYRA N/A
- YSG N/A
- 52 Week Low
- TYRA $6.42
- YSG $2.60
- 52 Week High
- TYRA $29.60
- YSG $6.13
- Technical
- Relative Strength Index (RSI)
- TYRA 45.95
- YSG 45.88
- Support Level
- TYRA $8.23
- YSG $3.42
- Resistance Level
- TYRA $8.80
- YSG $4.23
- Average True Range (ATR)
- TYRA 0.70
- YSG 0.39
- MACD
- TYRA 0.19
- YSG -0.08
- Stochastic Oscillator
- TYRA 75.30
- YSG 32.00
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The Group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.